ABEO - ABEONA THERAPEUTICS INC.
IEX Last Trade
5.63
0 0%
Share volume: 4,959
Last Updated: Fri 27 Dec 2024 08:29:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$5.63
0.00
0.00%
Fundamental analysis
6%
Profitability
0%
Dept financing
6%
Liquidity
46%
Performance
2%
Performance
5 Days
0.53%
1 Month
-10.76%
3 Months
-2.89%
6 Months
36.52%
1 Year
11.72%
2 Year
137.34%
Key data
Stock price
$5.63
DAY RANGE
$5.56 - $5.72
52 WEEK RANGE
$3.28 - $9.01
52 WEEK CHANGE
$14.17
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Vishwas Seshadri
Region: US
Website: abeonatherapeutics.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abeonatherapeutics.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Abeona Therapeutics Inc. develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A.
Recent news